Andreu Soldevila, CEO of the company, was a chairman at the 2nd BioTech Pharma Summit: Biosimilars & Biologics at Oporto. In this convention there were global regulators, officials, healthcare actors as well as industry leaders, discussing key concepts about general trends of the biopharmaceutical market and biosimilar regulation. It is known that market access strategies, clinical development, commercialisation, manufacturing and bioanalytics are critical points for this industry. That is why this two days’ congress allow the possibility of learn about a variety of case studies presented, taking conclusions about each of them to mitigate the risk that can be generated when developing a biosimilar.